Completed PHASE4 INTERVENTIONAL 4-arm NCT00306228

Role of Tirofiban and the Paclitaxel Eluting Stent in Postfibrinolysis Angioplasty (GRACIA3)

A Randomised Trial to Evaluate the Role of Paclitaxel Eluting Stent and Tirofiban to Improve the Results of Facilitated PCI in the Treatment of Acute ST- Segment Elevation Myocardial Infarction

Sponsor: GRACIA Group

Conditions Myocardial Infarction

Interventions Postfibrinolysis percutaneous coronary intervention

Updated 7 times since 2017 Last updated: Sep 25, 2009 Started: Oct 31, 2004 Primary completion: Jan 31, 2008 Completion: Jan 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Myocardial Infarction and is currently completed. GRACIA Group leads this study, which shows 7 recorded versions since 2004 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

7 versions recorded

Nov 2024 — Present [monthly]

Completed PHASE4
Sep 2024 — Nov 2024 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GRACIA Group
Ministry of Science and Innovation, Spain
Spanish Ministry of Health.

Data source: GRACIA Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Valladolid, Spain